<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Stories by James Street on Medium]]></title>
        <description><![CDATA[Stories by James Street on Medium]]></description>
        <link>https://medium.com/@james.street.phd?source=rss-76cc3863b2da------2</link>
        <image>
            <url>https://cdn-images-1.medium.com/fit/c/150/150/1*mBRlPOGJMLkk1E5C7aJcfQ.jpeg</url>
            <title>Stories by James Street on Medium</title>
            <link>https://medium.com/@james.street.phd?source=rss-76cc3863b2da------2</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Tue, 17 Nov 2026 11:00:59 GMT</lastBuildDate>
        <atom:link href="https://medium.com/@james.street.phd/feed" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[Management of Osteoporosis and Osteopenia: Part 2 — Supplements and Other Treatments]]></title>
            <description><![CDATA[<div class="medium-feed-item"><p class="medium-feed-image"><a href="https://medium.com/watts-the-science/management-of-osteoporosis-and-osteopenia-part-2-supplements-and-other-treatments-e5bdd19c361d?source=rss-76cc3863b2da------2"><img src="https://cdn-images-1.medium.com/max/989/0*LKkgCke5KF5SmGYQ.jpeg" width="989"></a></p><p class="medium-feed-snippet">The number of drugs and supplements for prevention and treatment of osteoporosis and osteopenia is quite extensive, so I have split this&#x2026;</p><p class="medium-feed-link"><a href="https://medium.com/watts-the-science/management-of-osteoporosis-and-osteopenia-part-2-supplements-and-other-treatments-e5bdd19c361d?source=rss-76cc3863b2da------2">Continue reading on Street Science »</a></p></div>]]></description>
            <link>https://medium.com/watts-the-science/management-of-osteoporosis-and-osteopenia-part-2-supplements-and-other-treatments-e5bdd19c361d?source=rss-76cc3863b2da------2</link>
            <guid isPermaLink="false">https://medium.com/p/e5bdd19c361d</guid>
            <category><![CDATA[osteoporosis-supplements]]></category>
            <category><![CDATA[osteopenia]]></category>
            <category><![CDATA[osteoporosis-drugs-market]]></category>
            <category><![CDATA[osteoporosis]]></category>
            <dc:creator><![CDATA[James Street]]></dc:creator>
            <pubDate>Mon, 16 Nov 2026 17:37:05 GMT</pubDate>
            <atom:updated>2026-11-16T17:37:05.822Z</atom:updated>
        </item>
        <item>
            <title><![CDATA[Management of Osteoporosis and Osteopenia: Part 1 — What Your Doctor Says]]></title>
            <description><![CDATA[<div class="medium-feed-item"><p class="medium-feed-image"><a href="https://medium.com/watts-the-science/management-of-osteoporosis-and-osteopenia-part-1-what-your-doctor-says-d3adfa79d9f1?source=rss-76cc3863b2da------2"><img src="https://cdn-images-1.medium.com/max/2408/1*23oYG7bMqP_t-mgzSU3GWg.jpeg" width="2408"></a></p><p class="medium-feed-snippet">The number of drugs, supplements, and other approaches for prevention and treatment of osteoporosis and osteopenia is quite extensive, so&#x2026;</p><p class="medium-feed-link"><a href="https://medium.com/watts-the-science/management-of-osteoporosis-and-osteopenia-part-1-what-your-doctor-says-d3adfa79d9f1?source=rss-76cc3863b2da------2">Continue reading on Street Science »</a></p></div>]]></description>
            <link>https://medium.com/watts-the-science/management-of-osteoporosis-and-osteopenia-part-1-what-your-doctor-says-d3adfa79d9f1?source=rss-76cc3863b2da------2</link>
            <guid isPermaLink="false">https://medium.com/p/d3adfa79d9f1</guid>
            <category><![CDATA[calcium-and-vitamin-d]]></category>
            <category><![CDATA[osteoporosis]]></category>
            <category><![CDATA[osteopenia-industry]]></category>
            <category><![CDATA[osteopenia]]></category>
            <dc:creator><![CDATA[James Street]]></dc:creator>
            <pubDate>Mon, 09 Nov 2026 17:57:03 GMT</pubDate>
            <atom:updated>2026-11-16T18:03:04.922Z</atom:updated>
        </item>
        <item>
            <title><![CDATA[Comparing Athletic Performance by Gender and Implications for Transgender Competition]]></title>
            <description><![CDATA[<div class="medium-feed-item"><p class="medium-feed-image"><a href="https://medium.com/watts-the-science/comparing-athletic-performance-by-gender-and-implications-for-transgender-competition-1a57355ba02a?source=rss-76cc3863b2da------2"><img src="https://cdn-images-1.medium.com/max/600/1*wgBG5R5bozif6Rw-JcHDfQ.png" width="600"></a></p><p class="medium-feed-snippet">I recently wrote about the controversy of transgender athletes in sport. As part of that article I pointed to a commonly used graphic&#x2026;</p><p class="medium-feed-link"><a href="https://medium.com/watts-the-science/comparing-athletic-performance-by-gender-and-implications-for-transgender-competition-1a57355ba02a?source=rss-76cc3863b2da------2">Continue reading on Street Science »</a></p></div>]]></description>
            <link>https://medium.com/watts-the-science/comparing-athletic-performance-by-gender-and-implications-for-transgender-competition-1a57355ba02a?source=rss-76cc3863b2da------2</link>
            <guid isPermaLink="false">https://medium.com/p/1a57355ba02a</guid>
            <category><![CDATA[running]]></category>
            <category><![CDATA[transgender]]></category>
            <category><![CDATA[sports-running-parkrun]]></category>
            <category><![CDATA[athletic-performance]]></category>
            <dc:creator><![CDATA[James Street]]></dc:creator>
            <pubDate>Mon, 02 Nov 2026 16:20:56 GMT</pubDate>
            <atom:updated>2026-11-02T16:20:56.104Z</atom:updated>
        </item>
        <item>
            <title><![CDATA[Time On Bike vs Time On Feet]]></title>
            <description><![CDATA[<div class="medium-feed-item"><p class="medium-feed-image"><a href="https://medium.com/watts-the-science/time-on-bike-vs-time-on-feet-0d17339ceee7?source=rss-76cc3863b2da------2"><img src="https://cdn-images-1.medium.com/max/1060/1*LJ9n8LAk9Blg1VvhFiuMJg.jpeg" width="1060"></a></p><p class="medium-feed-snippet">I have previously attempted to estimate how much training volume on a bike relates to a similar amount of training on a bike. The original&#x2026;</p><p class="medium-feed-link"><a href="https://medium.com/watts-the-science/time-on-bike-vs-time-on-feet-0d17339ceee7?source=rss-76cc3863b2da------2">Continue reading on Street Science »</a></p></div>]]></description>
            <link>https://medium.com/watts-the-science/time-on-bike-vs-time-on-feet-0d17339ceee7?source=rss-76cc3863b2da------2</link>
            <guid isPermaLink="false">https://medium.com/p/0d17339ceee7</guid>
            <category><![CDATA[running]]></category>
            <category><![CDATA[strava]]></category>
            <category><![CDATA[cycling]]></category>
            <dc:creator><![CDATA[James Street]]></dc:creator>
            <pubDate>Mon, 26 Oct 2026 20:39:58 GMT</pubDate>
            <atom:updated>2026-10-26T20:39:58.272Z</atom:updated>
        </item>
        <item>
            <title><![CDATA[Bring Out Your Dead: The Plague in 2026]]></title>
            <link>https://medium.com/watts-the-science/bring-out-your-dead-the-plague-in-2026-f05dd41218b0?source=rss-76cc3863b2da------2</link>
            <guid isPermaLink="false">https://medium.com/p/f05dd41218b0</guid>
            <category><![CDATA[bubonic-plague]]></category>
            <category><![CDATA[plague]]></category>
            <dc:creator><![CDATA[James Street]]></dc:creator>
            <pubDate>Mon, 12 Oct 2026 15:52:48 GMT</pubDate>
            <atom:updated>2026-10-14T15:52:41.095Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/975/1*9uOnmoHLiK2nLEIN6gOQlQ.png" /><figcaption>Bubonic Plague is endemic in prairie dogs, which are common across the Western US.</figcaption></figure><p><a href="https://www.theguardian.com/world/2026/oct/06/plague-epidemic-risk-russia-low-death-darya-shipilova-who">A Lab tech in Irkutsk, Russia died last week</a> after breaking a vial purportedly containing plague pathogens. The Russians described the death as being pneumonia of unknown etiology. Although quarantine measures for possibly exposed personnel have been put in place, and WHO has described the risk of a wider outbreak of plague as low, the media has become quite excited by this incident. Whether this interest is driven by the lab leak theory of COVID-19 and the possibility that the Russians are working on some form of weaponized plague, or just because of the range of recent infectious disease outbreaks around the world (eg ebola, measles) is not clear. So how worried should we be?</p><p><strong>Types of Plague</strong></p><p>The Black Death was a plague pandemic that killed 30%–60% of the entire population of Europe in the 14th century. As a result, even today the idea that it might return evinces an emotional response. The plague is caused by the bacterium <em>Yersinia pestis</em>, and comes in 3 forms, bubonic plague, septiciemic plague, and pneumonic plague.</p><p><em>Bubonic Plague</em></p><p>Bubonic plague is the form of the disease most closely associated with the Black Death, but septicemic and pneumonic plague may also have played a role. Bubonic plague during the Black Death was spread primarily from small animals like rats to humans via fleas; cutting out the middle man, a direct bite from an infected animal could also result in infection. Improvements in sanitation have prevented such a plague from occurring in developed countries today (isolated outbreaks do occur occasionally in underdeveloped societies).</p><p>Symptoms of bubonic plague include flu like symptoms (fever, headache, vomiting) and swollen lymph nodes. The swollen lymph nodes, aka buboes, typically in the groin, armpits, and neck were the tell-tale sign of the Black Death. Without treatment bubonic plague results in death in up to 40%–60% of patients within 10 days.</p><p><em>Septicemic Plague</em></p><p>Septicemic plague occurs when the bacterium infects the bloodstream. Initial symptoms are similar to bubonic plague, but ultimately leads to internal and external bleeding, gangrene, and septicemic shock. Untreated septicemic plague is almost always fatal, often within hours of displaying symptoms. This type of plague spreads via flea bites (like bubonic plague), and is a potential complication of bubonic plague.</p><p><em>Pneumonic Plague</em></p><p>The Russian tech Darya Shipilova seemingly died of pneumonic plague (at least they said it was pneumonia). Pneumonic plague is caused by <em>Yersinia pestis </em>infection of the lungs. Symptoms include fever, headache, shortness of breath, chest pain, and coughing (including coughing up blood). It is almost always fatal.</p><p>Pneumonic plague can be transmitted via respiratory droplets, i.e. coughs and sneezes, much like other respiratory infections. Transmission requires face-to-face contact, usually within 3 to 6 feet, so social distancing and masking can effectively prevent spread. While pneumonic plague is regarded as moderately to highly contagious, the chances of transmission are somewhat lower than for viruses like influenza or measles.</p><p>Some have suggested that pneumonic plague may have actually caused more deaths than bubonic plague during the Black Death. Fun Fact: The nursery rhyme Ring Around the Rosie has long been though to refer to the Black Death, possibly suggesting a role for pneumonic plague. However, the rhyme does not appear in the historical record until the late 19th century, 500 years after the Black Death swept across Europe.</p><p><strong>Treatment</strong></p><p>Antibiotics can be used to treat bubonic plague, substantially reducing the mortality rate to 1%–15%. Streptomycin, gentamycin, doxycycline, ciprofloxacin, and chloramphenicol have all demonstrated efficacy against plague. While all forms of plague are readily treatable, deaths do occur, primarily due to late diagnosis.</p><p>A vaccine against the plague is available. However, since cases of bubonic plague are rare, routine vaccination is not conducted. The vaccine is reserved for purposes of prevention during outbreaks.</p><p><strong>Modern Day Plague</strong></p><p>Although we rarely hear about bubonic plague today, unlike smallpox, the disease has not been eradicated. However, despite improved sanitation cases of bubonic plague do occur. Approximately 7–9 cases of bubonic plague are reported each year in the US, mainly in the Western states (<strong>Figure 1</strong>).</p><p><strong>Figure 1</strong>. Case reports of human plague 1970–2023 (<a href="https://www.cdc.gov/plague/maps-statistics/index.html">CDC</a>).</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/975/1*jFxAxc7FJTUP_Ff9EpNmAQ.png" /></figure><p>Close contact with wild animals (or their fleas) is almost always the cause of plague in humans. Although larger animals can be a source of plague (a veterinarian died of pneumonic plague after conducting an autopsy on a mountain lion; <a href="https://academic.oup.com/cid/article-abstract/49/3/e33/501093">Wong, 2009</a>), most cases relate to smaller animals. Plague is endemic in prairie dogs, ground squirrels, and chipmunks which are common in places like Colorado and New Mexico.</p><p><strong>Conclusions</strong></p><p>The concern in the media about this isolated case of a lab tech in Russia is likely driven by worries about weaponization of plague. There is no evidence of this, and even the media has refrained from overtly suggesting it (at least as far as I have seen). Furthermore, <em>Yersinia pestis </em>is likely a poor candidate as an agent of biological warfare since it is both treatable with antibiotics and preventable with a vaccine. Plague is also not as transmissible as other infectious diseases such as COVID-19, measles, or influenza. A single case of plague in Siberia is not a cause for concern. The risk of catching bubonic plague from a squirrel or a prairie dog right here in America is a much greater real and present danger.</p><p><strong>Reference:</strong></p><p><a href="https://academic.oup.com/cid/article-abstract/49/3/e33/501093">Wong D, Wild MA, Walburger MA et al. <em>Clin Infect Dis. </em>2009;49:e33-e38</a>.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=f05dd41218b0" width="1" height="1" alt=""><hr><p><a href="https://medium.com/watts-the-science/bring-out-your-dead-the-plague-in-2026-f05dd41218b0">Bring Out Your Dead: The Plague in 2026</a> was originally published in <a href="https://medium.com/watts-the-science">Street Science</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Nicotinamide Riboside]]></title>
            <link>https://medium.com/watts-the-science/nicotinamide-riboside-eb6388408bc0?source=rss-76cc3863b2da------2</link>
            <guid isPermaLink="false">https://medium.com/p/eb6388408bc0</guid>
            <category><![CDATA[nicotinamide-riboside]]></category>
            <category><![CDATA[running]]></category>
            <dc:creator><![CDATA[James Street]]></dc:creator>
            <pubDate>Mon, 05 Oct 2026 16:13:34 GMT</pubDate>
            <atom:updated>2026-10-14T15:52:15.437Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/975/1*0CZ2igWnsAbg3zrMxX0Gvg.png" /><figcaption>Not sure if this is running or walking, but he is powered by nicotinamide riboside.</figcaption></figure><p>I have a friend who has been trying to sell me on the benefits of nicotinamide riboside for quite some years now. Not only is Bob (name changed to protect the guilty) is a very accomplished runner over distances from 1 to 200 miles, he is also an academic biochemist. Nicotinamide riboside is purported to boost cellular energy and improve metabolic health, hence improving muscle function and endurance — traits that are highly desirable for athletes. So did Bob fall foul to the propaganda on the running forums or did he apply his biochemistry knowledge. As a biochemist myself, this week I take a look at nicotinamide riboside as part of my nutritional supplement series.</p><p><strong>What is Nicotinamide Riboside?</strong></p><p>Oxidative respiration in the mitochondria of every cell in the body results in the conversion of NAD+ to NADH via the Kreb’s cycle. Nicotinamide riboside is a form of vitamin B3 (niacin), a precursor of NAD (nicotinamide adenine dinucleotide). It would make sense, therefore, that nicotinamide riboside may be effective at ensuring the body has sufficient levels of NAD+ to power the body during exercise.</p><p>On the most basic nutritional and biochemical levels, there are two primary problems with the idea that nicotinamide riboside supplementation might not help athletic performance. Firstly, vitamin B3 deficiencies are very rare in the industrialized world, meaning that adding more likely won’t improve nutritional status. Secondly, the limiting factor for energy generation is not the supply of NAD+/NADH, but the supply of glucose to feed into glycolysis and/or the supply of acetyl CoA into the Kreb’s cycle; acetyl CoA can be formed via glycolysis or the burning of fat.</p><p><strong>Preclinical Evidence</strong></p><p>There have been a number of studies of nicotinamide riboside supplementation in mice. Genetic depletion of NAD in a mouse model results in decreased muscle strength and endurance that can be reversed with nicotinamide riboside supplementation (<a href="https://pubmed.ncbi.nlm.nih.gov/27508874/">Frederick, 2016</a>). Other mouse models of NAD depletion, (which can occur in ageing, obesity, type 2 diabetes, and fatty liver disease, despite the scarcity of vitamin B3 deficiency), have been shown to reverse the negative effects of ageing and diet-induced obesity (<a href="https://pubmed.ncbi.nlm.nih.gov/29264533">Elhassan, 2017</a>).</p><p>At least one study found that exercise capacity and running distance was improved in mice (<a href="https://pubmed.ncbi.nlm.nih.gov/22682224/">Cantó, 2012</a>). However, the opposite was found to be the case in rats (<a href="https://pubmed.ncbi.nlm.nih.gov/27489522/">Kourtzidis, 2016</a>; <a href="https://pubmed.ncbi.nlm.nih.gov/30007015/">Kourtzidis, 2018</a>).</p><p>However, one of the problems with preclinical models is that they allow for more extreme metabolic conditions than occur in the real world to be studied. Furthermore, animal studies don’t always translate to humans anyway. So, while there may be some hope that nicotinamide riboside may have some benefits, it needs to be studied in humans.</p><p><strong>Human Studies of Nicotinamide Riboside</strong></p><p>A PubMed search for clinical trials of nicotinamide riboside yields 24 results. After excluding 3 papers because they did not report results relating to nicotinamide riboside in humans, there are 21 papers describing 19 different studies (<strong>Table 1</strong>). These studies cover a range of conditions from Parkinson’s disease and ataxia telangiectasia to kidney disease and hypertension. There is no significant body of work in any particular condition.</p><p><strong>Table 1</strong>. Summary of Clinical Studies of Nicotinamide Riboside</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*iFLK1W202Y_Y5akWBP3hBw.jpeg" /><figcaption>Links to published studies can be found at the bottom of the page.</figcaption></figure><p>Twelve of the nineteen studies reported increases in NAD levels and/or other metabolic measures in blood and other compartments; two studies reported no change in NAD levels, and two did not report NAD levels. The other studies reported only changes in inflammatory markers, liver function tests, and estrogen E2/E1 ratio. This indicates that nicotinamide riboside does indeed increase NAD levels, but is this clinically relevant?</p><p>Eight of the 19 studies did not report any actual clinical endpoints. Results were negative/neutral in an additional 6 studies. In the other 5 studies, there was a trend toward improvements in body composition, sleep, arterial stiffness and endothelial function, blood pressure, cardiopulmonary fitness, neuromotor symptoms and eye movement, and symptoms of menopause. With the exception of menopause, all of these studies were in people with pre-existing conditions, including Werner’s syndrome, ataxia telangiectasia, Friedrich’s ataxia, peripheral artery disease, hypertension, or obesity.</p><p>Looking specifically at the studies that examined parameters that may translate to running, there is little to suggest that nicotinamide riboside may have a role as a supplement. A study in middle- and old-aged healthy subjects found no improvement in exercise capacity (<a href="https://pubmed.ncbi.nlm.nih.gov/29599478/">Martens, 2018</a>). Another study conducted in older patients found that nicotinamide riboside had no effect on recovery from muscle injury (<a href="https://pubmed.ncbi.nlm.nih.gov/35998039/">Jensen, 2022</a>). In patients with chronic kidney disease nicotinamide riboside had no effect on VO2max or work efficiency (<a href="https://pubmed.ncbi.nlm.nih.gov/35998039/">Ahmadi, 2023</a>).</p><p>The only positive study that had any possible relevance to running was an improvement in cardiopulmonary fitness in patients with Friedrich’s ataxia, which is a genetic disease characterized by a reduction in mitochondrial frataxin (<a href="https://pubmed.ncbi.nlm.nih.gov/42009009/">Lin, 2026</a>). Frataxin in turn helps to regulate cellular energy and protects the cell from oxidative stress. A shortage of frataxin results in a build up of iron in the mitochondria leading to nerve and heart muscle degeneration. The possible applicability of this result to even the most extreme running is remote.</p><p>None of these studies investigated the effects of nicotinamide riboside in athletes. As a result, no conclusions can be made about its use for improving running performance.</p><p><strong>Conclusions</strong></p><p>While having more of a chemical that is involved in energy production seems like it might be of value, if it isn’t the actual energy source it won’t really help. NAD/NADH is like a battery — having a bigger battery with more lithium ions isn’t going to increase the range of your EV car if you can’t plug it in.</p><p>While all of these studies find that nicotinamide riboside is safe, there is very little evidence that it has any clinical or physiologic effects outside of very specific conditions that result in a deficiency of NAD. There is even less evidence that it has any effect on athletic performance. Both Bob the runner and Bob the biochemist should be ashamed of themselves.</p><p><strong>References</strong></p><p><a href="https://pubmed.ncbi.nlm.nih.gov/27508874/">Frederick DW, Loro E, Liu L, et al. <em>Cell Metabolism. </em>2016;24:269–282</a>.</p><p><a href="https://pubmed.ncbi.nlm.nih.gov/29264533">Elhassan YS, Philp AA, Lavery GG. <em>J Endocr Soc. </em>2017;1:816–835</a>.</p><p><a href="https://pubmed.ncbi.nlm.nih.gov/22682224/">Cantó C, Houtkooper RH, Pirinen E, et al. <em>Cell Metab. </em>2012;15:838–847</a>.</p><p><a href="https://pubmed.ncbi.nlm.nih.gov/27489522/">Kourtzidis IA, Stoupas AT, Gioris IS, et al. <em>J Int Soc Sports Nutr. </em>2016;13:32</a>.</p><p><a href="https://pubmed.ncbi.nlm.nih.gov/30007015/">Kourtzidis IA, Dolopikou CF, Tsiftsis AN, et al. <em>Exp Physiol. </em>2018;103:1357–1366</a>.</p><p><a href="https://pubmed.ncbi.nlm.nih.gov/35235774/">Brakedal B, Dölle C, Riemer F, et al. <em>Cell Metab. </em>2022;34:396–407</a>.</p><p><a href="https://pubmed.ncbi.nlm.nih.gov/29599478/">Martens CR, Denman BA, Mazzo MR et al. <em>Nat Commun. </em>2018;9:1286</a>.</p><p><a href="https://pubmed.ncbi.nlm.nih.gov/32320006/">Remie CME, Roumans KHM, Moonen MPB, et al. <em>Am J Clin Nutr. </em>2020;112:413–426</a>.</p><p><a href="https://pubmed.ncbi.nlm.nih.gov/40459998/">Shoji M, Kato H, Koshizaka M, et al. <em>Aging Cell. </em>2025;24:e70093</a>.</p><p><a href="https://pubmed.ncbi.nlm.nih.gov/31412242/">Elhassan YS, Kluckova K, Fletcher RS, et al. <em>Cell Rep. </em>2019;28:1717–1728</a>.</p><p><a href="https://pubmed.ncbi.nlm.nih.gov/36515353/">Vreones M, Mustapic M, Moaddel R, et al. <em>Aging Cell. </em>2023;22:e13754</a>.</p><p><a href="https://pubmed.ncbi.nlm.nih.gov/37899683/">Presterud R, Deng WH, Wennerström AB, et al. <em>Mov Disord. </em>2024;39:360–369</a>.</p><p><a href="https://pubmed.ncbi.nlm.nih.gov/40479886/">Svarvas Z, Reyff ZA, Peterfi A, et al. <em>J Pharmacol Exp Ther. </em>2025;392:103607</a>.</p><p><a href="https://pubmed.ncbi.nlm.nih.gov/40770531/">Lin Y, Zeidan RS, Lapierre-Nguyen S, et al. <em>Geroscience. </em>2025;47:6895–6908</a>.</p><p><a href="https://pubmed.ncbi.nlm.nih.gov/41540253/">Christen S, Redeuil K, Goulet L, et al. <em>Nat Metab. </em>2026;8:62–73</a>.</p><p><a href="https://pubmed.ncbi.nlm.nih.gov/37159264/">Ahmadi A, Begue G, Valencia AP, et al. <em>JCI Insight. </em>2023;8:e167274</a>.</p><p><a href="https://pubmed.ncbi.nlm.nih.gov/35998039/">Jensen JB, Dollerup OL, Møller AB, et al. <em>JCI Insight. </em>2022;7:e158314</a>.</p><p><a href="https://pubmed.ncbi.nlm.nih.gov/42478598/">Martens CR, Decker KP, DeConne TM, et al. <em>Alzheimers Dement. </em>2026;22:e71605</a>.</p><p><a href="https://pubmed.ncbi.nlm.nih.gov/41502156/">Thomas S, Ben-Davies R, Cetinkaya-Fisgin A, et al <em>J Peripher Nerv Syst. </em>2026;31:e70101</a>.</p><p><a href="https://pubmed.ncbi.nlm.nih.gov/42048163/">Han K, Klein RJ, Recupero TC, et al. <em>JCI Insight. </em>2026;11:e203826</a>.</p><p><a href="https://pubmed.ncbi.nlm.nih.gov/42211736/">Holmes HE, Srivastava K, Scalici JM, et al. <em>Front Aging. </em>2026;7:1773667</a>.</p><p><a href="https://pubmed.ncbi.nlm.nih.gov/31710095/">Dollerup OL, Chubanava S, Agerholm M, et al. <em>J Physiol. </em>2020;598:731–754</a>.</p><p><a href="https://pubmed.ncbi.nlm.nih.gov/31390002/">Dollerup OL, Trammell SAJ, Hartmann B, et al. <em>J Clin Endocrinol Metab. </em>2019;104:5703–5714</a>.</p><p><a href="https://pubmed.ncbi.nlm.nih.gov/29992272/">Dollerup OL,Christensen B, Svart M, et al. <em>Am J Clin Nutr. </em>2018;108:343–353</a>.</p><p><a href="https://pubmed.ncbi.nlm.nih.gov/36082508/">Dellinger RW, Holmes RE, Hu-Seliger T, et al. <em>Hepatology. </em>2023;78:863–877</a>.</p><p><a href="https://pubmed.ncbi.nlm.nih.gov/42009009/">Lin KY, Bucha A, McSweeney K, et al. <em>Lancet Neurol. </em>2026;25:469–481. Friederich</a>.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=eb6388408bc0" width="1" height="1" alt=""><hr><p><a href="https://medium.com/watts-the-science/nicotinamide-riboside-eb6388408bc0">Nicotinamide Riboside</a> was originally published in <a href="https://medium.com/watts-the-science">Street Science</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Trans and Intersex Athletes in Sport]]></title>
            <link>https://medium.com/watts-the-science/trans-and-intersex-athletes-in-sport-0634cd1b47a1?source=rss-76cc3863b2da------2</link>
            <guid isPermaLink="false">https://medium.com/p/0634cd1b47a1</guid>
            <category><![CDATA[intersex]]></category>
            <category><![CDATA[sports]]></category>
            <category><![CDATA[transgender]]></category>
            <dc:creator><![CDATA[James Street]]></dc:creator>
            <pubDate>Mon, 28 Sep 2026 17:41:33 GMT</pubDate>
            <atom:updated>2026-09-28T17:41:33.698Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/975/1*NJTH5vRvePOeOvSXR3GRsw.png" /><figcaption>Intersex athlete Caster Semenya of South Africa competing at the World Athletics Championships, 2017.</figcaption></figure><p>There has been much gnashing of teeth and wringing of hands in the US the last few weeks about trans athletes in sport. There are ballot measures here in Colorado about banning trans athletes in high school sports, as well as banning transition treatment for minors. Is this a real concern or just manufactured outrage to stoke the culture wars ahead of the Mid-term elections? While I think we all know the answer, what are the actual facts?</p><p><strong>How Big is the Problem?</strong></p><p>The Human Rights Campaign defines transgender as relating to gender identity rather than a clinical status. According to the Williams Institute at the UCLA School of Law, about 2.8 million Americans over the age of 13 identify as transgender; this amounts to ~1% of the population.</p><p>Of the 2.8 million people who identify as transgender about half have undergone gender-affirming hormone therapy (GAHT) and a quarter have undergone gender-affirming surgery. Assuming the outcry about trans athletes doesn’t generally apply to women transitioning to men, this means that there are about 700,000 trans women who have undergone GAHT, and 350,000 who have undergone surgery.</p><p>There is more than one type of surgical procedure, falling into two main categories, top and bottom surgeries — what this means is probably what you think. Top surgeries are more common and involve the chest and breasts, and bottom surgeries involve the genitals. The latter is much less common. Transition surgery in adults is more than twice as common as in adolescents, and is almost unheard of in children under 14 years of age. Overall, there are probably only about 35,000 trans women in the US who have undergone full transition surgery.</p><p>Given the different degrees of transgender, there is something of an ethical dilemma as to which of these groups should be allowed to participate in women’s sports. Should you have undergone bottom and top surgery, GAHT, or is it enough to merely identify as trans? Maybe the science of gender transition will help resolve this.</p><p><strong>Identifying As Trans</strong></p><p>A trans woman who merely identifies as a woman without undergoing any form of treatment, has all the physical advantages of being a man. Continued production of testosterone increases lean body mass and strength. In sport this gives substantial physical advantages. <strong>Figure 1</strong> shows the women’s world track and field records compared to the age group records for 14–15 year-old boys. In 2017 the US Women’s National Team lost 5–2 to FC Dallas U-15 team.</p><p><strong>Figure 1</strong>. Women’s Track and Field World Records vs Age Group Records for Boys Aged 14–15 Years</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/298/1*wgBG5R5bozif6Rw-JcHDfQ.png" /></figure><p>couple of years into puberty and the testosterone that goes with it, has already put them comfortably ahead of the best women ever. This would suggest that trans women who have not undergone any treatment tend to have significant physical advantages.</p><p><strong>Women to Men</strong></p><p>A quick word about female to male transition. While this is certainly an important topic, it is also fair to say that it is of little consequence when it comes to sport. While there are a few examples of competitive trans men, including in wrestling, boxing, triathlon, and swimming, the culture war is mainly focused on trans females.</p><p>Trans men take synthetic testosterone to achieve levels of 300–1000ng/dL, in the range of cis men. After three years of testosterone treatment, performance among trans men was in fact similar to that of cis men, suggesting that they can compete in sports on a par (<a href="https://pubmed.ncbi.nlm.nih.gov/36271916/">Chiccarelli, 2022</a>). It should be noted, however, that testosterone treatment does not compensate for smaller body frame and height differences.</p><p><strong>Men to Women</strong></p><p>There appears to be a general presumption that trans women who have undergone treatment have physical advantages over cis women, i.e. that the benefits of testosterone during puberty persist beyond GAHT and/or gender reassignment surgery.</p><p>It is certainly true that height and skeletal benefits of going through puberty as a man persist (although transition can lead to bone loss in the long-term). Just being bigger and taller is a benefit in many sports, like basketball. One of the most famous sports personalities to undergo gender reassignment is Bruce/Kylie Jenner who won the Olympic decathlon in 1976. At 6’2” and 194 pounds he was much larger and taller than most elite female heptathletes. The 2024 Olympic champion in the heptathlon was Nafissatou Thiam; she is one of the tallest heptathletes ever at a similar 6’2”, but only weighed 152 pounds.</p><p>Men in general have a greater relative wingspan or ape index than women (the ratio of distance from finger tip to finger tip with arms outstretched to height), allowing their arms to act as more efficient levers for swimming. A swimmer with the wingspan of Michael Phelps (not trans as far as I know) would not lose that reach after transitioning. The best example of this is Princeton trans female swimmer Lia Thompson who has a wingspan a considerable 4” longer than her height. She went from being an average NCAA swimmer as a man to NCAA champion as a woman, despite losing lean mass.</p><p>However, many of the advantages that a trans athlete has following GHAT or surgery are lost over 2–3 years. Men who transition to women lose advantages in lung function (<a href="https://journal.chestnet.org/article/S0012-3692(25)00423-4/abstract">Braga, 2025</a>) and overall fitness (<a href="https://www.ovid.com/jnls/acsm-msse/abstract/10.1249/mss.0000000000003536~physical-fitness-and-exercise-performance-of-transgender?redirectionsource=fulltextview">Saitong, 2025</a>). In one study, cardiopulmonary capacity was reduced, but VO2max remained higher than in cis women (<a href="https://pubmed.ncbi.nlm.nih.gov/36195433/">Alvares, 2022</a>). However, a different study observed worse VO2max, as well as lower relative jump height; grip strength was maintained (<a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11137468/">Hamilton, 2024</a>). These findings were confirmed in a recent meta-analysis of 52 studies found that transgender women had similar upper and lower body strength, and VO2max compared to cis women (<a href="https://pubmed.ncbi.nlm.nih.gov/41633803/">Sieczkowska, 2026</a>).</p><p>Taken together this suggests that trans women retain no substantial advantages for endurance type sports. Support for the lack of benefit in endurance sports comes from a study by Harper et al. who found that age grading performance for trans women (9 runners and 1 swimmer) remained the same before and after undergoing GAHT (<a href="https://pubmed.ncbi.nlm.nih.gov/40804607/">Harper, 2025</a>).</p><p>Overall trans women lose almost all of their physical advantage over women after 2–3 years of GAHT or post-surgery — most sports bodies require an interval of this sort before competing as a woman. Trans women do retain the size of their body frame, which can be an advantage in some disciplines.</p><p><strong>What Does GAHT Actually Do?</strong></p><p>GAHT essentially involves the use of androgen blockers (spironolactone) and estrogens (estradiol). Androgen blockers are used to reduce testosterone levels to &lt;50 ng/dL, within the normal range for cis women; removal of the testes has a similar effect. Other anti-androgens include gonadotropin-releasing hormone and 5-alpha reductase inhibitors. Estrogen supplementation can cause body fat redistribution, muscle mass reduction, and skin softening to give a more feminine appearance. Progestogens are also sometimes given to promote development of breasts (though some trans women also have breast enhancement surgery).</p><p>These treatments do not come without side effects. Estrogens can cause mood changes, headaches, nausea, elevated blood pressure, and increased risk of blood clots, stroke, and gallstones. Androgen blockers can cause low libido, erectile dysfunction, hot flashes, and bone loss. Spironolactone is also a diuretic, so can lead to frequent urination, increased thirst, low blood pressure, and hyperkalemia. All of this will have an impact on an athletes ability to train effectively.</p><p>Notably all of these drugs are on the WADA (World Anti-Doping Agency) banned list. WADA can also differentiate between natural testosterone and the synthetic testosterone used by trans men. By that token, trans athletes are currently barred from participating in sports which follow WADA guidelines and actually conduct drug tests.</p><p><strong>Psychology of Transgender</strong></p><p>This is a complex topic, and sits at the root of much of the debate around transgender, especially among adolescents. Although gender dysphoria is listed in DSM-5, it is not regarded as a mental illness. However, a transgender diagnosis is associated with a significantly higher rate of comorbid psychiatric diagnoses than controls (58% vs 13.6%; p&lt;0.0005; <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC6830528/">Wanta, 2019</a>). This included a higher rate of major depressive disorder of 31% vs 12% for controls. The confounding nature of comorbid psychiatric conditions makes getting an accurate diagnosis especially important.</p><p>A correct diagnosis is especially important among adolescents. Twenty five percent of all people identifying as transgender are 13–17 years of age. While this large percentage likely reflects greater acceptance among today’s youth, the general confusion of puberty must be considered as a factor in this age group, especially in the context of psychiatric comorbidities.</p><p>Unfortunately, there are few studies investigating the impact of transition on psychological parameters. One of the few studies conducted did find significant improvements in self-worth, social and psychological well-being, sexual and physical appearance, quality of life, and gender dysphoria (<a href="https://www.psychiatrist.com/pcc/gender-affirming-surgeries-gender-dysphoria-quality-life">Bhela, 2025</a>). However, such studies are difficult to conduct and interpret given the logistic issues of an appropriate control. The fact that other studies have reported increased risk of mortality and psychiatric outcomes emphasizes this point (<a href="https://pubmed.ncbi.nlm.nih.gov/21364939/">Dhejne, 2011</a>). While the observations in this study are presumably real, the outcomes are likely due to the underlying comorbidities.</p><p>One of the arguments against gender-affirming surgery is that people often regret the decision. However, data shows that the rate of regret is actually around 1% (<a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC8099405/">Bustos, 2021</a>). While this rate may rise if the rigorous psychiatric evaluation prior to surgery becomes more lax as demand increases, it is not currently a major cause for concern.</p><p><strong>Intersex/Differences of Sexual Development</strong></p><p>Before we get into whether transgender athletes should be allowed to participate in the sport of their chosen gender, let’s take a look at something that should be less controversial, intersex athletes. The problems with transgender athletes in sport were preceded by how to manage athletes with differences of sexual development (DSD or intersex).</p><p>World Athletics and other sports governing bodies are yet to figure out a good solution for these athletes. Perhaps the most famous intersex athlete is Caster Semenya who won World and Olympic gold medals over 800m. She is a woman who was born with a 5α-reductase 2 deficiency that resulted in testosterone levels in the normal male range. World Athletics response was to require her to take anti-androgens to reduce her natural testosterone levels, but only if she was to compete in certain events.</p><p>In a sport where genetic advantage is often the difference between first and second (you don’t see many short basketball players), choosing which genetic traits are allowed is a slippery slope to discrimination. More importantly, requiring an athlete to take drugs, and risk potential side effects, to compete clouds the waters on the role of drugs in a sport that has had its fair share of doping scandals. If DSD athletes can’t participate in sports, there is little hope that transgender athletes will be treated any better.</p><p><strong>Where to Draw the Line</strong></p><p>Data suggests that athletes who have undergone surgical transition and/or GAHT have few if any advantages. As such this group should likely be allowed to compete, at least at the recreational level. Given the difficulty sports governing bodies have maintaining faith in clean sport, allowing trans athletes at the highest level of sport (i.e. professional sports) is probably counterproductive. By professional sports I mean sport where money might become a factor, including Olympic level sport and US college level sport where the reward is a scholarship and/or NIL deal. Barring trans women from this level of participation would impact very few athletes; there are currently fewer than 10 trans athletes currently competing in NCAA sports.</p><p>Given that the physical advantage of a male body is lost after 2–3 years, there is no need to exclude these athletes from participating in recreational sport. However, these trans women should have to sit out 2 years, as some governing bodies already require, while their bodies adjust. After that a woman being beaten in her age group at the local 5k by a trans woman probably lost to a better and/or more dedicated athlete, not a man.</p><p>The more difficult category is that of people who identify as transgender, but don’t actually undergo treatment. Men who merely identify as women retain all the physical advantages of being a man. She probably shouldn’t be picking up awards at the local 5k or playing on the pub’s women’s soccer team. This problem is more complex for adolescents and should likely be addressed on an individual basis in consultation with a psychologist. However, school is a time in our lives where we are forced to conform to the whims of the system; for the minority of transgender students who care about sport, participation according to biological and chemical gender is a sacrifice that may have to be made.</p><p><strong>Conclusions</strong></p><p>The transgender women in sport controversy is a solution in search of a problem. There are no men in the WNBA. Indeed, there are a vanishingly small number of trans women participating in high level sport at all. Furthermore, dealing with the side effects of treatment, as well as psychiatric comorbidities, likely make maintaining a high-level training program prohibitive for most people. At the more recreational level, the advantages of once having been a man are quite limited, and few actually participate to a degree that it actually bothers anyone.</p><p>The only real controversy is how to treat those who identify as transgender but have not committed to treatment. For these people, they should have to decide between what gender they want to be and how they want to participate in sport.</p><p><strong>References:</strong></p><p><a href="https://pubmed.ncbi.nlm.nih.gov/36271916/">Chiccarelli E, Aden J, Ahrendt D, et al. <em>Mil Med. </em>2023;188:e1588-e1595</a>.</p><p><a href="https://journal.chestnet.org/article/S0012-3692(25)00423-4/abstract">Braga F, Milani M, Fachetti AC, et al. <em>Chest. </em>2025;168:697–709</a>.</p><p><a href="https://www.ovid.com/jnls/acsm-msse/abstract/10.1249/mss.0000000000003536~physical-fitness-and-exercise-performance-of-transgender?redirectionsource=fulltextview">Saitong A, Naeowong W, Susom D, Tanaka H. <em>Med Sci Sports Exercise. </em>2025;57:134–143</a>.</p><p><a href="https://pubmed.ncbi.nlm.nih.gov/36195433/">Alvares LAM, Santos MR, Souza FR, et al. <em>Be J Sports Med. </em>2022;56:1292–1298</a>.</p><p><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11137468/">Hamilton B, Brown A, Montagner-Moraes S, et al. <em>Br J Sports Med. </em>2024;58:586–597</a>.</p><p><a href="https://pubmed.ncbi.nlm.nih.gov/41633803/">Siezkowska SM, Mazzolani BC, Coimbra DR, et al. <em>Br J Sports Med. </em>2026;60:198–210</a>.</p><p><a href="https://pubmed.ncbi.nlm.nih.gov/40804607/">Harper J, Blagrove RC, Hunsicker E, et al. <em>Eur J Sport Sci. </em>2025;25:e70036</a>.</p><p><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC6830528/">Wanta JW, Niforatos JD, Durbak E, et al. <em>Transgend Health. </em>2019;4:313–315</a>.</p><p><a href="https://www.psychiatrist.com/pcc/gender-affirming-surgeries-gender-dysphoria-quality-life">Bhela JS, Saboor S, Ansari M, et al. <em>Prim Care Companion CNS Disord. </em>2025;27:23r03677</a>.</p><p><a href="https://pubmed.ncbi.nlm.nih.gov/21364939/">Dhejne C, Lichtenstein P, Boman M, et al. <em>PLoS One. </em>2011;6:e16885</a>.</p><p><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC8099405/">Bustos VP, Bustos SS, Mascaro A, et al. <em>Plast Reconstr Surg Glob Open. </em>2021;9:e3477</a>.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=0634cd1b47a1" width="1" height="1" alt=""><hr><p><a href="https://medium.com/watts-the-science/trans-and-intersex-athletes-in-sport-0634cd1b47a1">Trans and Intersex Athletes in Sport</a> was originally published in <a href="https://medium.com/watts-the-science">Street Science</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Turmeric: The Natural Alternative to OTC Pain Killers]]></title>
            <link>https://medium.com/watts-the-science/turmeric-the-natural-alternative-to-otc-pain-killers-03a89c0849f9?source=rss-76cc3863b2da------2</link>
            <guid isPermaLink="false">https://medium.com/p/03a89c0849f9</guid>
            <category><![CDATA[turmeric]]></category>
            <category><![CDATA[knee-pain]]></category>
            <category><![CDATA[curcumin]]></category>
            <category><![CDATA[nsaids-drug]]></category>
            <category><![CDATA[muscle-soreness]]></category>
            <dc:creator><![CDATA[James Street]]></dc:creator>
            <pubDate>Mon, 21 Sep 2026 15:52:55 GMT</pubDate>
            <atom:updated>2026-10-14T15:53:07.476Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*i_2agIUadVby2HLq2e0kvg.jpeg" /></figure><p>Regular readers of this column will know that I am dubious about the efficacy of dietary supplements. <a href="https://medium.com/watts-the-science/gras-dietary-supplements-are-safe-but-are-they-effective-1dacbff62eee">This skepticism</a> is driven more by a lack of evidence supporting health claims rather than any antipathy to non-pharmaceutical drugs. That said, there is clinical evidence to support use of some dietary supplements, eg, <a href="https://medium.com/watts-the-science/dietary-supplements-for-the-knees-3fdbbb478321">glucosamine and collagen</a> for pain associated with knee osteoarthritis. Another supplement often recommended for treatment of muscle and joint pain is turmeric.</p><p>As someone who suffers from ulcerative colitis, I am advised to avoid NSAIDS such as naproxen and ibuprofen as they can exacerbate the condition. I don’t drink that much, but run club, beer, and acetaminophen (aka paracetamol) may not mix well either. The possibility that turmeric may act as an effective alternative to over-the counter (OTC) analgesics is, therefore, attractive. To that end, I will attempt to review the clinical evidence for turmeric as an anti-inflammatory/pain reliever.</p><p><strong>What Is Turmeric?</strong></p><p>Turmeric is a bright yellow/orange spice extracted from the root of the plant <em>Curcuma longa</em> of the ginger family, and actually contains as many as 200 different chemicals. It has been used as medicine to treat a variety of conditions for thousands of years. The primary active ingredient in turmeric, however, is actually curcumin.</p><p>Turmeric has been clearly demonstrated to have anti-inflammatory properties. Focusing just on clinical studies, a formulation of turmeric in combination with black pepper and ginger (more on the role of black pepper later), was found to reduce the key pro-inflammatory compound prostaglandin E2 (PGE2) to a similar degree as the NASID naproxen (<a href="https://pubmed.ncbi.nlm.nih.gov/32180294/">Heidari-Beni, 2020</a>). Turmeric has also been shown to reduce levels of inflammatory markers C-reactive protein (CRP) and tumor necrosis factor-alpha (TNF-α) to a greater degree than acetaminophen (<a href="https://pubmed.ncbi.nlm.nih.gov/33516238/">Singhal, 2021</a>).</p><p>Turmeric/curcumin are also often classified as antioxidants. Studies have shown that supplementation is associated with improvements in total antioxidant capacity, malondialdehyde, and superoxide dismutase (<a href="https://www.sciencedirect.com/science/article/abs/pii/S1043466623000224">Dehzad, 2023</a>). However, in general, clinical evidence that antioxidants have any important clinical benefit is quite limited (<a href="https://pubmed.ncbi.nlm.nih.gov/23635359/">Wahlqvist 2013</a>). Hence, any clinical activity of turmeric is likely due to its demonstrated anti-inflammatory effects.</p><p><strong>Turmeric for Musculoskeletal Pain and Inflammation</strong></p><p>A PubMed search was conducted for randomized clinical trials of turmeric in humans (this also captured trials of curcumin). A total of 25 studies were identified. Studies were further reviewed to eliminate turmeric in combination with other herbal products (except black pepper and ginger that are included to improve bioavailability), or studies that did not report clinical outcomes.</p><p>A number of placebo-controlled trials showed benefit relative to placebo in management of knee osteoarthritis and muscle soreness (<strong>Table 1</strong>). Importantly, there were no negative studies (there was one at last partially neutral study; <a href="https://pubmed.ncbi.nlm.nih.gov/32749918/">Calderón-Pérez, 2021</a>), suggesting that turmeric consistently provides benefit.</p><p><strong>Table 1</strong>. Summary of Randomized, Placebo-Controlled Trials of Turmeric</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*DS4jVHtVTsJ7-_M76twu-A.png" /><figcaption>bid, twice daily; KOOS, Knee Injury and Osteoarthritis Outcome Score; PGADA, Patient Global Assessment of Disease Activity; VAS, visual analogue scale; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index.</figcaption></figure><p>The potential value of turmeric though is as an alternative to OTC analgesics like NSAIDS and acetaminophen. Superiority to placebo is of little value if it is less effective than other available options. <strong>Table 2</strong> summarizes three studies in which turmeric supplements were compared to acetaminophen or ibuprofen. In all three studies, turmeric supplements were found to be as effective as typical doses of OTC pain relievers for chronic knee osteoarthritis pain. A meta-analysis including many of the trials discussed here, including 1810 adults with knee osteoarthritis showed better efficacy compared to placebo and similar efficacy as compared to NSAIDs (<a href="https://pubmed.ncbi.nlm.nih.gov/33511486/">Wang, 2021</a>).</p><p><strong>Table 2</strong>. Summary of randomized controlled trials comparing turmeric to common OTC pain relievers.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/739/1*Bu-qAy39M3qszPNskI-qcw.png" /><figcaption>bid, twice daily; tid, thrice daily; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index.</figcaption></figure><p>Most of these studies were conducted in patients with pain associated with chronic knee osteoarthritis. Knee osteoarthritis is a frequently used model for study of musculoskeletal pain; the lack of studies for other kinds of musculoskeletal pain should not be seen as a major limitation of the scientific literature. The body of evidence showing the effects of turmeric on inflammatory markers, and efficacy in placebo-controlled and single arm studies give further confidence that turmeric is effective beyond knee osteoarthritis.</p><p><strong>Other Potential Health Effects</strong></p><p>Health claims have also been made for turmeric and curcumin with respect to cancer, cardiovascular disease, inflammatory disease, metabolic disease, neurological disease, and skin diseases. Unlike many dietary supplements and naturally occurring drug products, turmeric and curcumin have been extensively studied with over 7000 papers. While most of these are based on preclinical studies, a recent systematic review identified 148 clinical trials for turmeric and 440 for curcumin (<a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10111629/">Kunnumakkara, 2023</a>).</p><p>Although we have focused here on the use of turmeric for management of musculoskeletal pain and inflammation, turmeric has also shown promise in management of inflammatory disorders (psoriasis, Crohn’s disease, ulcerative cholitis, and gall bladder diseases), cancer, dysmenorrhea, post-surgical pain (hysterectomy), kidney disease, and diabetes (<a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10111629/">Kunnumakkara, 2023</a>). However, in almost all cases, the effects were limited to improvements in disease biomarkers, and were small relative to established pharmaceutical alternatives; Kunnumakkara concluded that turmeric might be an adjunct to standard medication, not an alternative (<a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10111629/">Kunnumakkara, 2023</a>).</p><p><strong>Safety</strong></p><p>The most common side effects of turmeric are those that are listed for many drugs and supplements and include upset stomach, nausea, diarrhea, constipation, and gas. The chances of experiencing these and the severity, are related to the actual dose you take. There have been reports of severe allergic reactions and liver toxicity after taking turmeric, but these events are quite rare and reversible after stopping the supplement. However, on balance the meta-anaylsis by Wang et al. found that turmeric was associated with 12% fewer side effects than NSAIDs (<a href="https://pubmed.ncbi.nlm.nih.gov/33511486/">Wang, 2021</a>).</p><p><strong>Dosing</strong></p><p>The main outstanding question about use of turmeric is how much to take. Most clinical studies have used 500–2000 mg turmeric per day or 500–1500 mg curcumin extract per day. Commercially available products tend to recommend 1500 mg/day. However, it is necessary to add 5–10 mg of black pepper (active ingredient piperine) to reduce first pass metabolism and achieve the anti-inflammatory effects; black pepper increases bioavailability by up to 2000% (<a href="https://pubmed.ncbi.nlm.nih.gov/9619120/">Shoba, 1998</a>). Some commercially available turmeric products include black pepper, so be careful to make sure you buy these formulations (<strong>Figure 1</strong>), unless you like mainlining black pepper.</p><p><strong>Figure 1</strong>. A Sampling of Commercially Available Turmeric with Black Pepper Products</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/533/1*RceuRbUkes4SQkAFIGXJOA.png" /></figure><p><strong>Conclusions</strong></p><p>Turmeric provides one of the rare cases of a non-patentable, naturally occurring product that has demonstrated efficacy and safety. Because turmeric and curcumin products are already available and marketable, there is no incentive to conduct additional clinical trials to gain FDA approval for specific indications.</p><p>Turmeric is a safe and effective alternative to NSAIDs or acetaminophen for management of musculoskeletal pain. Unlike most dietary supplement products, it has been extensively studied in both preclinical and clinical studies, so its use is supported by abundant evidence.</p><p><strong>References:</strong></p><p><a href="https://pubmed.ncbi.nlm.nih.gov/32180294/">Heidari-Beni M, Moravejolahkami AR, Gorgian P, et al. <em>Phyother Res. </em>2020;34:2067–2073</a>.</p><p><a href="https://pubmed.ncbi.nlm.nih.gov/33516238/">Singhal S, Hasan N, Nirmal K, et al. <em>Trials. </em>2021;22:105</a>.</p><p><a href="https://www.sciencedirect.com/science/article/abs/pii/S1043466623000224">Dehzad MJ, Ghalandari H, Nouri M, Askarpour M. <em>Cytokine. </em>2023;164:156144</a>.</p><p><a href="https://pubmed.ncbi.nlm.nih.gov/23635359/">Wahlqvist ML. <em>Asia Pac J Clin Nutr. </em>2013;22:171–176.</a></p><p><a href="https://pubmed.ncbi.nlm.nih.gov/32749918/">Calderón-Pérez L, Llauradó E, Companys J, et al. <em>J Med Food. </em>2021;24:436–440.</a></p><p><a href="https://pubmed.ncbi.nlm.nih.gov/35010916/">Lopresti AL, Smith SJ, Jackson-Michel S, Fairchild T. <em>Nutrients. </em>2021;14:41</a>.</p><p><a href="https://pubmed.ncbi.nlm.nih.gov/32926799/">Wang Z, Jones G, Winzenberg, et al. <em>Ann Intern Med. </em>2020;173:861–869</a>.</p><p><a href="https://pubmed.ncbi.nlm.nih.gov/41040018/">Schönenberger KA, Laval J, Woods T, et al. <em>J Int Soc Sports Nutr. </em>2025;22:2568048</a>.</p><p><a href="https://pubmed.ncbi.nlm.nih.gov/33066856/">Raj JP, Venkatachalam S, Racha P, et al. <em>Complement Ther Med. </em>2020;53:102522</a>.</p><p><a href="https://pubmed.ncbi.nlm.nih.gov/31351488/">Henrotin Y, Malaise M, Wittoek R, et al. <em>Arthritis Res Ther. </em>2019;21:179</a>.</p><p><a href="https://pubmed.ncbi.nlm.nih.gov/23242572/">Madhu K, Chanda K, Saji MJ. <em>Inflammopharmacology. </em>2013;21:129–136</a>.</p><p><a href="https://pubmed.ncbi.nlm.nih.gov/33511486/">Wang Z, Singh A, Jones G, et al. <em>Curr Rheumatol Rep. </em>2021;23:11</a>.</p><p><a href="https://pubmed.ncbi.nlm.nih.gov/24672232/">Kuptniratsaikul V, Dajpratham P, Taechaarpornkul W, et al. <em>Clin Interv Aging. </em>2014;9:451–458</a>.</p><p><a href="https://pubmed.ncbi.nlm.nih.gov/19678780/">Kuptniratsaikul V, Thanakhumtorn S, Chinswangwatanakul P, et al. <em>J Altern Complement Med. </em>2009;15:891–897</a>.</p><p><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10111629/">Kunnumakkara AB, Hegde M, Parama D, et al. <em>ACS Pharmacol Transl Sci. </em>2023;6:447–518</a>.</p><p><a href="https://pubmed.ncbi.nlm.nih.gov/9619120/">Shoba G, Joy D, Joseph T, et al. <em>Planta Med. </em>1998;64:353–356</a>.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=03a89c0849f9" width="1" height="1" alt=""><hr><p><a href="https://medium.com/watts-the-science/turmeric-the-natural-alternative-to-otc-pain-killers-03a89c0849f9">Turmeric: The Natural Alternative to OTC Pain Killers</a> was originally published in <a href="https://medium.com/watts-the-science">Street Science</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Are E-Bikes Over-Powered?]]></title>
            <link>https://medium.com/watts-the-science/are-e-bikes-over-powered-2c2fae1a50a2?source=rss-76cc3863b2da------2</link>
            <guid isPermaLink="false">https://medium.com/p/2c2fae1a50a2</guid>
            <category><![CDATA[ebike]]></category>
            <category><![CDATA[cycling]]></category>
            <dc:creator><![CDATA[James Street]]></dc:creator>
            <pubDate>Mon, 14 Sep 2026 16:04:05 GMT</pubDate>
            <atom:updated>2026-10-14T15:53:47.404Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*MPXpG_6fRg0yngHsbBbAZA.jpeg" /><figcaption>Class 2 350W Ebike.</figcaption></figure><p>Earlier this year the cycling world got very excited about 5-time Tour de France winner <a href="https://www.cyclingweekly.com/racing/did-tadej-pogacar-just-share-his-secret-power-data-on-strava">Tadej Pogacar accidentally posting his power data on Strava</a>. His functional threshold power (FTP) was revealed to be about 415W; FTP is the highest average power a cyclist can maintain for about an hour. His maximum power (i.e. all out sprint power) exceeded 650W. Legendary sprinter Mark Cavendish could hit 1300–1500W for a few seconds during the closing stages of a race. Some top track sprinters can hit 2000W.</p><p>To put these power numbers in perspective, the sprinters putting out &gt;1300W are reaching speeds close to 50 mph. Pogacar can average over 26 mph for more than 6 hours; and that includes a good amount of climbing.</p><p>While most people were busy being awed by the incredible numbers Pogacar was generating, I was drawn to the fact that he wasn’t reaching the 750W sustained power of many e-bikes on the roads in America. Do recreational cyclists and commuters need to achieve speeds of professional bike racers? I have attempted to put the various issues about e-bikes into this context.</p><p><strong>How Much Power Do You Actually Need?</strong></p><p>Few cyclists have the need to generate 1500W for any period of time. That said, few cyclists are as skinny as Tadej Pogacar. Fewer non-cyclists (who are the ones most likely to buy an e-bike) are that skinny. Pogacar is reported to weight about 66 kg or 145 lb, which means he generates about 6.2 W/kg. I am not sure if the W/kg includes his bike, but this does become relevant for e-bikes as they can be quite heavy. To make the maths easier, let’s assume his bike weighs 5 lb (not realistic but close enough for government work), for a total mass of 150 lb. That means someone who weighs 300 lb (including bike) needs to generate 12.4 W/kg, or maximum sustained power of 830W to keep up with Tadej Pogacar.</p><p>But does someone on an e-bike need to keep up? The speeds that professional cyclists maintain are closer to that of cars than of the typical cyclist. A good amateur cyclist can maintain 150–200W for an hour, less than half that of Pogacar; these guys are still averaging around 20 mph. Even assuming that the good amateur weighs the same 150 lb (including bike) as Pogacar, the hypothetical 300 lb including bike only needs 415W to keep up.</p><p>According to Strava, most of my rides these days average about 100W (might be slightly higher as I probably lied to Strava about my weight), with an average speed of around 15 mph if the hills aren’t too big. And it is a while since I was 145 lb. However, I am still faster than most cyclists; I have finished well inside the top half of the various bike races I have done in the past year. So, our hypothetical e-biker wouldn’t need to generate more than 200W to keep up with me. Maybe 300W would allow him to easily average 20 mph or negotiate a steep hill.</p><p>So how powerful a motor does the average e-bike need to have? Bearing in mind that our rider can probably generate at least a few watts himself/herself, say 50W, the e-bike motor only needs to generate 250W to propel a largish person at 20 mph.</p><p><strong>Classes of E-Bike</strong></p><p>Before we get too deep into the power of e-bikes, let’s take a moment to review the 3 legal classes of e-bikes in the US. The key differences between these bikes are summarized in <strong>Table 1</strong>. While Class 3 bikes are subject to more regulation, they still do not require license, registration, and insurance. Despite that, they can easily outpace top professional cyclists, with a 28-mph top speed.</p><p><strong>Table 1</strong>. Characteristics of E-bikes.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/684/1*g1fYqo0aOay0VFIlzvYYkw.png" /></figure><p><strong>How Powerful Are Typical E-Bikes?</strong></p><p>Some e-bikes do in fact deliver 250W. I have a friend with a 250W e-mountain bike who can easily keep up with me using just 20% of the power, or 50W. That makes sense, it gives just enough boost to keep pace with a somewhat stronger rider. In the UK and EU e-bikes are regulated such that they cannot deliver more than 250W (<strong>Figure 1</strong>), or go above 15 mph. However, Federal regulations in the US only limit e-bikes to 750W (some state variations apply). Watch out if you are in Brazil.</p><p><strong>Figure 1</strong>. E-bike Power Limitations by Country (<a href="https://www.hovsco.com/blogs/news/what-are-international-e-bike-laws-and-motor-power-restrictions-in-2025">HOVSCO</a>).</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/684/1*KgVFlCner5MYi4EZdx2aWw.png" /></figure><p>While e-bikes in the US can be much more powerful than in Europe, the reason that they are not much faster is that there are mechanisms to limit their top speed. However, these speed limiters can be circumvented to allow otherwise legal e-bikes to go much faster. This has led to <a href="https://www.nytimes.com/2023/07/29/health/ebikes-safety-teens.html">numerous articles</a> about the dangers of e-bikes.</p><p>In theory, any e-bike that exceeds these limits is essentially classified as a motor vehicle and is subject to registration, licensing, and insurance, as well as not being allowed in bike lanes. This applies even if the e-bike can be propelled via human power alone.</p><p>Complicating things further, many e-bike brands advertise peak power ratings far above the nominal 750W limit. A quick skim of Amazon shows that many brands actually promote the peak power rating rather than the nominal rating, with values from 1000–2500W. This power level is only available for short bursts, and is intended to help get you started or get up a particularly steep hill. But in practice, even in the presence of a speed limiter, this means that these machines can reach maximum speed alarmingly quickly (3–6 seconds by some estimates).</p><p>In addition, another class of e-bike is becoming increasingly prevalent; these are the e-motos. These machines have sustained power outputs as high as 2500W or more, and are capable of speeds of 50–60 mph. These are most likely the ones who don’t ever bother to use the front wheel. E-motos are not allowed on shared trails or bike paths, and many are not street legal at all.</p><p>However, many of these e-motos are being sold through on-line retailers to people who think they are buying a legal e-bike. I have never seen one of these e-motos with a license plate. But I have seen them in many places that such a machine shouldn’t be. Actually, they are only legal on private property, unless properly licensed and insured.</p><p><strong>Safety</strong></p><p>My social media feed is awash with reports of cycling incidents from around the world. While there are certainly incidents involving acoustic bikes, most of these actually involve e-bikes, many of which are not actually legal. Of course, the majority of crashes are actually caused by inattentive and sometimes positively antagonistic drivers.</p><p>Regardless of fault, when an e-bike is involved we must acknowledge that the severity of any injuries is compounded by the speed of the machine. Furthermore e-bikes tend to be quite heavy, so are more difficult to handle, increasing the risk. At speed, the braking distance will also be much longer than that of a regular bicycle. This is all Newton’s Second Law of Motion (<em>F=ma</em>; force = mass times acceleration). Most regular cyclists aren’t going to go all out and hit top speed downtown. But an e-bike rider can hit those speeds with ease.</p><p>The problem here is that many recreational cyclists have switched from a regular bike traveling at about 12 mph to an e-bike traveling 20 mph or more, with rapid acceleration. Even with a speed limiter the safety issues are compounded. Add in the rising popularity and the potential danger becomes clear.</p><p><strong>Popularity</strong></p><p>E-bikes have become increasingly popular in recent years. People have discovered that they can commute to work without arriving in a sweaty mess on an e-bike. Many cities have become more bicycle friendly, limiting cars and installing bicycle infrastructure. Places like Paris, London, and New York have set default speed limits on most streets at 19–25 mph. When you can easily breeze past traffic jams at 15–20 mph e-bikes are actually much faster than other modes of transport.</p><p><strong>The Infrastructure Problem</strong></p><p>The problem with e-bikes that can accelerate rapidly and maintain much higher speeds than regular bicycles is that they are starting to pose the same threats to pedestrians and cyclists in bike lanes and shared paths (shared with pedestrians and horses) that cars do on the road.</p><p>I don’t really have a problem with Class 1 or even Class 2 e-bikes on trails. However, I don’t really want e-bikes blasting by me at 30+ mph when I am slogging up a hill in the bike lane at 10 mph, and not just because I think they are cheating and make me look bad.</p><p>Some areas now have posted speed limits of 15–20 mph on bike lanes and shared paths, though there is little evidence of enforcement. While I may or may not occasionally exceed these limits on my regular bike, I am frequently passed by e-bikes that are going well over the posted speed limit.</p><p>A better way to ensure safety on shared trails perhaps is to ban Class 3 bikes. Many communities have put up signs barring Class 2 and 3 e-bikes from shared trails (<strong>Figure 2</strong>). Despite this I saw multiple Class 2, Class 3, and e-motos on a 20-mile ride the other day. In other words, there is no enforcement of these regulations, and local police in many jurisdictions don’t even know how to make these distinctions anyway.</p><p><strong>Figure 2</strong>. E-bike Regulations on Shared Trails in Colorado Springs.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/643/1*R12YJ5tgYPv57pLmrYuSOw.png" /></figure><p>I also am not keen on unlicensed and uninsured e-bikes on the road holding up traffic either. The problem with all this is that there is no alternative infrastructure for Class 3 bikes and e-motos. Given that regular bicycle infrastructure is lacking and remains controversial in many areas, the chances of dedicated infrastructure for these more powerful machines is unlikely any time soon.</p><p><strong>Conclusions</strong></p><p>Earlier we asked the question as to how much power was actually needed, and came up with an answer of 250W. This equates to the e-bike regulations in UK and Europe. Even in those countries, e-bikes draw a lot of controversy. E-bikes rated at 750W, as in the US, are far more powerful than anyone would ever need for recreational cycling or commuting. There is no need — and little opportunity — to ride at the speed of professional bike racers on an e-bike. Any other use of e-bikes is in place of a car, and should be regulated as such. E-bikes in the US are massively over powered for what is needed and/or safe.</p><p>In the United States, the lack of regulation and understanding about e-bikes and e-motos has led to a modern Wild West where people just ride wherever they want as fast as they want, despite limited attempts at regulation. There is a clear need for enforced regulation of e-bikes, both at point of sale and on roads and trails in the US, as well as clear education about the differences between different e-bike classes and e-motos. Serious consideration should also be given to reducing the maximum sustained power of e-bikes.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=2c2fae1a50a2" width="1" height="1" alt=""><hr><p><a href="https://medium.com/watts-the-science/are-e-bikes-over-powered-2c2fae1a50a2">Are E-Bikes Over-Powered?</a> was originally published in <a href="https://medium.com/watts-the-science">Street Science</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Debunking Antivax Claims in Pediatric Immunisation]]></title>
            <link>https://medium.com/watts-the-science/debunking-antivax-claims-in-pediatric-immunisation-c17f060aad8a?source=rss-76cc3863b2da------2</link>
            <guid isPermaLink="false">https://medium.com/p/c17f060aad8a</guid>
            <category><![CDATA[pediatric-vaccines]]></category>
            <category><![CDATA[vaccination]]></category>
            <category><![CDATA[antivaxx]]></category>
            <dc:creator><![CDATA[James Street]]></dc:creator>
            <pubDate>Tue, 08 Sep 2026 15:43:02 GMT</pubDate>
            <atom:updated>2026-10-18T15:07:45.342Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/623/1*WA-Kk4RjdbOxYBqyKjYqaQ.png" /></figure><p>I’m really not sure what Randy Polansky’s position on pediatric vaccinations is, but I decided to take him up on the invitation to do my own research on the various claims of Dr. Paul Thomas.</p><blockquote><strong>The US is #1 In Infant Vaccines &amp; #1 in Infant Mortality.</strong></blockquote><p>Until recently the US recommended that children receive more vaccines than other countries. In that respect, the US is/was indeed #1 in infant vaccines. However, the CDC has recently changed guidance to eliminate routine vaccination for COVID-19, influenza, rotavirus, hepatitis A and B, meningococcal meningitis, and respiratory syncytial virus (RSV).</p><p>Looking at overall vaccine coverage, the <a href="https://www.theglobaleconomy.com/rankings/measles_immunization_rate/">US ranked 83rd</a> (out of 186 countries tracked) in the proportion of children vaccinated against measles, with a rate of 92% in 2024; <a href="https://www.theglobaleconomy.com/rankings/dpt_immunization_rate/">77th for diphtheria/tetatnus/pertussis</a> (rate of 94%); and <a href="https://www.theglobaleconomy.com/rankings/hepatitis_B_immunization_rate/">75th for hepatitis B</a> (rate of 93%). So the US is far from #1 for reaching all infants for basic immunisations.</p><p>The US also does not have the lowest infant mortality rate in the World. Indeed, the US ranked as having only the <a href="https://www.theglobaleconomy.com/rankings/infant_mortality/">52nd lowest infant mortality rate</a>, out of 187 countries in 2024; the infant mortality rate is 6%! Sri Lanka, China, Russia, and most European countries all had lower rates of infant mortality. In other words, despite having the <a href="https://www.theglobaleconomy.com/rankings/Health_spending_per_capita/">highest health spending per capita </a>of any country on Earth ($13,473.19 in 2023), US children actually have quite poor healthcare and health outcomes.</p><p><strong>Rating:<em> </em></strong><em>The US is #1 In Infant Vaccines &amp; #1 in Infant Mortality</em><strong><em> — </em>FALSE</strong></p><blockquote><strong>97% of infants DIED within 7 days of a vaccine.</strong></blockquote><blockquote><strong>The More We Vaccinate the Sicker Our Kids Are.</strong></blockquote><p>How many people do you know who have had a child? How many of those have had a child die? How many of these deaths occurred as a result of vaccination? We have established above that over 90% of infants receive an array of vaccines. But I doubt that you know more than one or two people who have experienced the death of a child, let alone after vaccination.</p><p>The reality is that routine immunizations account for 40% of the total decline in global infant mortality over the last 50 years, and saved the lives of over 100 million infants under 1 year of age (<a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)00850-X/fulltext">Shattock, 2024</a>).</p><p>Maybe he means that 97% of infants who died, died within 7 days of vaccination. We will look into the truth of this below, but language is important. Sloppy language that changes the meaning to the degree that it implies your baby will die if it gets vaccinated needs to be called out.</p><p><strong>Rating:<em> </em></strong><em>97% of infants DIED within 7 days of a vaccine</em><strong><em> — </em>FALSE</strong></p><p><strong>Rating:<em> </em></strong><em>The More We Vaccinate the Sicker Our Kids Are</em><strong><em> — </em>FALSE</strong></p><blockquote><strong>Sudden Infant Death Syndrome (SIDS) Occurred in 97% of Infants Within the First 7 Days After a Vaccine Was Given.</strong></blockquote><p>This statement is as outlandish as the broader statement, <em>97% of infants died within 7 days of vaccination</em>. However, let’s give the benefit of the doubt that this is just badly worded and for a second and assume it means that 97% of SIDS deaths occur within 7 days of a vaccination.</p><p>SIDS is the unexplained death of an infant before the first year of age. In 2024 there were <a href="https://www.cdc.gov/sudden-infant-death/data-research/data/index.html">1351 deaths from SIDS</a>. There were another 1099 deaths from other unknown causes, and 947 from proven accidental suffocation and strangulation in bed. A diagnosis of SIDS is only given after a thorough investigation, including autopsy, when any other cause can be ruled out. So, a vaccine-related death would be attributed to the vaccine and not listed as SIDS.</p><p>The link between vaccination and SIDS is another case of correlation without causation. SIDS occurs most commonly in children younger than 4 months, which is the same time frame as initial routine infant immunizations. Regardless, the trope of vaccines causing SIDS has persisted. Fortunately, this link has been extensively studied and debunked.</p><p>The first piece of evidence that vaccinations don’t cause SIDS is that the rate of SIDS has actually decreased by 50% since the introduction of routine vaccinations (<a href="https://pubmed.ncbi.nlm.nih.gov/17400342/">Vennemann, 2007</a>). The reason for this decrease is not clear, but may be merely the result of the American Academy of Pediatrics educational <em>Back to Sleep</em> campaign to help reduce the risk of SIDS (so may be another case of correlation without causation).</p><p>The original link between vaccines and SIDS arose from a story on the US TV show <em>20/20</em> in 1999 claiming that a 1-month-old girl died of SIDS 16 hours after receiving the second dose of the hepatitis B vaccine. Given the number of vaccinations and the number of SIDS deaths each year, <a href="https://www.chop.edu/vaccine-education-center/vaccine-safety/vaccines-and-other-conditions/sudden-infant-death-syndrome-sids">about 50 cases of SIDS within 24 hours of the hepatitis B vaccine are to be expected each year by chance alone</a>.</p><p>The actual claim we are looking at is SIDS deaths within 7 days of vaccination, which would be 350 SIDS deaths within 7 days of hepatitis B vaccination alone. Since deaths within 7 days of other vaccinations might also to be expected, it is possible that the number of SIDS deaths would actually expected to be higher than it is if there were any causal link.</p><p>Several large scale studies have shown that there is no association between vaccines and SIDS (<a href="https://www.sciencedirect.com/science/article/abs/pii/S0264410X17318273">Yang, 2018</a>; <a href="https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0016363">Traversa, 2011</a>; <a href="https://pubmed.ncbi.nlm.nih.gov/15247605/">Eriksen, 2004</a>; <a href="https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1046/j.1365-2125.2001.00341.x">Jonville-Bera, 2001</a>; <a href="https://onlinelibrary.wiley.com/doi/abs/10.1002/pds.619">Silvers, 2001</a>). Some studies, in fact, have found that vaccination was associated with a lower rate of SIDS (<a href="https://publications.aap.org/pediatrics/article-abstract/79/4/598/54397/Diphtheria-Tetanus-Pertussis-Immunization-and?redirectedFrom=fulltext?autologincheck=redirected">Hoffman, 1987</a>), including in the 7 days immediately following immunization (<a href="https://pubmed.ncbi.nlm.nih.gov/3261837/">Griffin, 1988</a>).</p><p><strong>Rating:</strong> <em>Sudden Infant Death Syndrome (SIDS) Occurred in 97% of Infants Within the First 7 Days After a Vaccine Was Given — </em><strong>FALSE</strong></p><blockquote><strong>Health Authorities Removed ‘Post Vaccine’ as an Official Cause of Death, so Medical Examiners Must Label ‘Vaccine-Induced Deaths’ as SIDS.</strong></blockquote><p>This is just not true. In fact, healthcare providers are legally required to report any death that occurs after a vaccination, regardless of cause. This includes death caused by being hit by a bus. All of these reports are investigated to determine the true cause of death. Furthermore, public health agencies recognize and report specific rare conditions that are associated with vaccination, including thrombosis with thrombocytopenia syndrome, anaphylaxis, myocarditis/pericarditis, and live vaccine complications.</p><p><strong>Rating:</strong> <em>Health Authorities Removed ‘Post Vaccine’ as an Official Cause of Death, so Medical Examiners Must Label ‘Vaccine-Induced Deaths’ as SIDS — </em><strong>FALSE</strong></p><blockquote><strong>The aluminum adjuvants used that are injected directly into the system, 97% is absorbed into the bloodstream and in infants, shuts down the breathing center of the brain.</strong></blockquote><p>Aluminium adjuvants are used to help boost the immune response to a vaccine, allowing for stronger and longer-lasting immunity; this also helps to reduce the amount of actual vaccine material applied. They work by slowing release of vaccine antigens and triggering mild inflammation at the injection site, thus increasing the immune response.</p><p>Most vaccinations are injected into the muscle, usually the arm. Any aluminium adjuvant in the vaccine is slowly absorbed into the bloodstream. Not sure where the 97% number comes from — it appears to be a convenient made-up scary number to cover a multitude of sins (see above) — but essentially all of it (100%) is eventually absorbed so it can be later excreted via the kidneys. Otherwise, you would eventually have an arm made of aluminium.</p><p>Antivaxxers have long suggested that aluminium adjuvants have negative sequelae, <a href="https://medium.com/watts-the-science/autism-causes-antivaxxers-9cc987269979">including causing autism</a>. A recent analysis of more than 1.2 million children found that aluminium exposure from vaccination during the first 2 years of life was not associated with increased rates of 50 disorders, including autism and other neurodevelopmental disorders, autoimmune disorders including atopic or allergic disorders (<a href="https://pubmed.ncbi.nlm.nih.gov/40658954/">Andersson, 2025</a>). Furthermore, despite the billions of doses of aluminium-adjuvanted vaccines dispensed worldwide, there have been no reports of related death (<a href="https://pubmed.ncbi.nlm.nih.gov/37983316/">Agency for Toxic Substances and Disease Registry, 2008</a>). In addition, there is no evidence that aluminium has any effect on the brain or breathing.</p><p><strong>Rating:<em> </em></strong><em>The aluminum adjuvants used that are injected directly into the system, 97% is absorbed into the bloodstream and in infants, shuts down the breathing center of the brain — </em><strong>FALSE</strong></p><blockquote><strong>Coined ‘Aluminum Adjuvant Apnea’ where infants, without warning, just stop breathing.</strong></blockquote><p>Aluminium adjuvant apnea is a made-up term, used by antivaxxers to promote their conspiracy theory about vaccines and SIDS. Some state that the term is an alternative to SIDS itself, implying that all SIDS is in fact caused by aluminium vaccine adjuvant.</p><p>A search for the phrase in quotes in the published literature (PubMed) returns precisely zero results. Dropping the quotes yields 4 papers, 2 about the efficacy (or lack thereof) of Gaviscon for treatment of sleep apnea in children, one in cats, and a 1992 case study published in Russian. Google searches direct you only to antivax FaceBook pages and the like. The volume of pages referring to a made up non-scientific (but scientific-sounding) term merely demonstrates the effectiveness of the social media feedback loop that drives conspiracy theories in the 21st century.</p><p><strong>Rating: </strong><em>Coined ‘Aluminum Adjuvant Apnea’ where infants, without warning, just stop breathing</em><strong> — FALSE</strong></p><p><strong>Conclusions</strong></p><p>The final piece of my own research was to look up Dr Thomas and see if he is in fact a real doctor. It turns out that his <a href="https://wmc.wa.gov/news/out-state-md-indefinitely-suspended">medical license was suspended</a> in 2023 for making “<em>false or misleading statements regarding the efficacy of treatments; and repeated gross negligence in the practice of medicine</em>.” This should not be a surprise given the irresponsible and unfounded statements we have reviewed here.</p><p>All of the statements made by Dr Thomas are verifiably false if you “<em>do your own research</em>.” The fact that so many people buy into these dangerous narratives is that it is often easier to tap into the disinformation feedback loop while doing your own research than tracking down the truth.</p><p>Bottom line, I agree with Randy Polansky that for our children’s sake, do some research. In this case I have done it for you, but when you do it yourself make sure you dig deep enough into appropriate scientific and medical resources to get the right answers.</p><p><strong>References:</strong></p><p><a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)00850-X/fulltext">Shattock AJ, Johnson HC, Sim SY, et al. <em>Lancet. </em>2024;403:2307–2316</a>.</p><p><a href="https://pubmed.ncbi.nlm.nih.gov/17400342/">Vennemann MMT, Hoffgen M, Bajanowski T, et al. <em>Vaccine. </em>2007;25:4875–4879</a>.</p><p><a href="https://www.sciencedirect.com/science/article/abs/pii/S0264410X17318273">Yang YT, Shaw J <em>Vaccine. </em>2018;36:595–598</a>.</p><p><a href="https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0016363">Traversa G, Spila-Alegiani S, Bianchi C, et al. <em>PLoS ONE. </em>2011;6:e16363</a>.</p><p><a href="https://pubmed.ncbi.nlm.nih.gov/15247605/">Eriksen EM, Perlman JA, Miller A, et al. <em>Pediatr Infect Dis J. </em>2004;23:656–661</a>.</p><p><a href="https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1046/j.1365-2125.2001.00341.x">Jonville-Bera AP, Autret-Leca E, Barbeillon F, et al. <em>Br J Clin Pharmacol. </em>2001;51:271–276</a>.</p><p><a href="https://onlinelibrary.wiley.com/doi/abs/10.1002/pds.619">Silvers LE, Ellenberg SS, Wise RP, et al. <em>Pharmacoepidemiol Drug Saf. </em>2001;10:279–285</a>.</p><p><a href="https://publications.aap.org/pediatrics/article-abstract/79/4/598/54397/Diphtheria-Tetanus-Pertussis-Immunization-and?redirectedFrom=fulltext?autologincheck=redirected">Hoffman HJ, Hunter JC, Damus K, et al. <em>Pediatrics. </em>1987;79:598–611</a>.</p><p><a href="https://pubmed.ncbi.nlm.nih.gov/3261837/">Griffin MR, Ray WA, Livengood JR, Schaffner W. <em>N Engl J Med. </em>1988;319:618–623</a>.</p><p><a href="https://pubmed.ncbi.nlm.nih.gov/40658954/">Andersson NW, Svalgaard IB, Hoffmann SS, Hviid A. <em>Ann Intern Med. </em>2025;178:1369–1377</a>.</p><p><a href="https://pubmed.ncbi.nlm.nih.gov/37983316/">Agency for Toxic Substances and Disease Registry (US). Toxicological Profile for Aluminum</a>, Atlanta, 2008.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=c17f060aad8a" width="1" height="1" alt=""><hr><p><a href="https://medium.com/watts-the-science/debunking-antivax-claims-in-pediatric-immunisation-c17f060aad8a">Debunking Antivax Claims in Pediatric Immunisation</a> was originally published in <a href="https://medium.com/watts-the-science">Street Science</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
    </channel>
</rss>